A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Rhenium-186 etidronic acid (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 24 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 16 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.